Jpmorgan Chase & CO Humacyte, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding HUMA
# of Institutions
135Shares Held
31MCall Options Held
323KPut Options Held
582K-
Black Rock Inc. New York, NY7.14MShares$36.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.73MShares$24 Million0.0% of portfolio
-
State Street Corp Boston, MA2.87MShares$14.5 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$9.44 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.6MShares$8.11 Million0.0% of portfolio
About Humacyte, Inc.
- Ticker HUMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,007,000
- Market Cap $522M
- Description
- Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...